Three gold, ivory, and blue light streams converging through a dark equilibrium plane
Pivotal carbon-fiber A-mark Pivotal
Prepared for Allison Houston
Your metabolic map

The equation
changed.

Your body did not stop working. The inputs changed, and one of them is still unknown.

Client-reported history
-45 lb Zepbound
6 months
Regained Treatment stopped
because of cost
-35 lb Compounded
tirzepatide
4 months Weight flat
at the current point
Most likely

Maintenance,
not a dead end.

A smaller body, a summer movement dip, lower active effort, and an unknown delivered amount can bring intake and output back into balance.

Smaller body Lower absolute energy needs after weight loss
Activity drift Travel, summer, and weeks of reduced movement
Possible lean-tissue loss Possible, not established without body-composition data
Unknown actual amount The vial concentration and delivered milligrams are unverified
1
Priority one

Verify the milligrams.

"90 units" tells us liquid volume. Without the vial concentration, it cannot tell us the milligrams delivered. The pharmacy or electronic prescription should resolve it.

90 units = liquid volume
Why a different lever

Three pathways. One more informed decision.

GIPGLP-1GLUCAGON

Retatrutide activates all three receptor pathways. A phase 2 human trial showed substantial weight loss. It did not authenticate any independently sourced vial or establish whether energy expenditure contributed.

My field judgment: My opinion comes from my clients, my own experience, reputable people in the industry, and what I can validate. The missing milligram record will help me dial the plan in more cleanly.

Precision before escalation.

The plateau is information.

01 VerifyConfirm the pharmacy concentration and actual milligrams.
02 ScreenYour medications, relevant history, and melanoma follow-up status.
03 BaselineBloodwork would provide cleaner starting context; it is not the first blocker.
04 PersonalizeAdjust from your response, not a one-size-fits-all schedule.
Client record Allison and Christopher, 14 Aug 2026 Weight history, activity context, dose uncertainty, and next questions.
Human phase 2 trial Jastreboff et al., NEJM 2023 · PMID 37366315 Retatrutide receptor profile and substantial trial weight loss.
Field judgment Christopher T. Barone Product judgment and the individualized next-move logic.